Page 1 of 1

From AACR meeting earlier in April/June

Posted: Tue Aug 18, 2020 8:00 am
by biopearl123

Re: From AACR meeting earlier in April/June

Posted: Thu Aug 20, 2020 3:23 am
by biopearl123
Well, its great to see early research in other areas. Be great if there were a clinical application in CML BC which basically heralds the end. I am perplexed by the 30mg/kg, 3x/wk dosing which is basically many fold higher than the 9.4 mg/kg q 3 weeks we are seeing used in MF. Am I looking at this right? If true clearly toxicity in human patients would be an issue but maybe the outlook in BC is so dismal, there could be some applicability. bp

Re: From AACR meeting earlier in April/June

Posted: Tue Aug 25, 2020 5:15 pm
by biopearl123
Looks like the doses in mice have been validated in the early Geron literature:

Utilization of Preclinical Xenograft Data in Predicting Human Imetelstat Target Tissue Concentrations

Re: From AACR meeting earlier in April/June

Posted: Tue Aug 25, 2020 5:28 pm
by biopearl123